|
Video: What is a Stock Split?
|
|
EyePoint Pharmaceuticals is a pharmaceutical company focused on developing and commercializing therapeutics for patients with eye disorders. Co.'s primary product candidate, EYP-19, is a potential sustained delivery intravitreal anti-VEGF treatment targeting wet age-related macular degeneration. YUTIQ 50 (fluocinolone acetonide intravitreal implant) 0.18 mg for intravitreal injection, is for the treatment of non-infectious uveitis affecting the posterior segment of the eye. DEXYCU® (dexamethasone intraocular suspension) 9%, for intraocular administration, is indicated for the treatment of post-operative ocular inflammation. According to our EyePoint Pharmaceuticals stock split history records, EyePoint Pharmaceuticals has had 1 split. | |
|
EyePoint Pharmaceuticals (EYPT) has 1 split in our EyePoint Pharmaceuticals stock split history database. The split for EYPT took place on December 09, 2020. This was a 1 for 10 reverse split, meaning for each 10 shares of EYPT owned pre-split, the shareholder now owned 1 share. For example, a 1000 share position pre-split, became a 100 share position following the split.
When a company such as EyePoint Pharmaceuticals conducts a reverse share split, it is usually because shares have fallen to a lower per-share pricepoint than the company would like. This can be important because, for example, certain types of mutual funds might have a limit governing which stocks they may buy, based upon per-share price. The $5 and $10 pricepoints tend to be important in this regard. Stock exchanges also tend to look at per-share price, setting a lower limit for listing eligibility. So when a company does a reverse split, it is looking mathematically at the market capitalization before and after the reverse split takes place, and concluding that if the market capitilization remains stable, the reduced share count should result in a higher price per share.
Looking at the EyePoint Pharmaceuticals stock split history from start to finish, an original position size of 1000 shares would have turned into 100 today. Below, we examine the compound annual growth rate — CAGR for short — of an investment into EyePoint Pharmaceuticals shares, starting with a $10,000 purchase of EYPT, presented on a split-history-adjusted basis factoring in the complete EyePoint Pharmaceuticals stock split history.
Growth of $10,000.00
Without Dividends Reinvested
|
Start date: |
05/06/2014 |
|
End date: |
05/03/2024 |
|
Start price/share: |
$37.00 |
|
End price/share: |
$19.74 |
|
Dividends collected/share: |
$0.00 |
|
Total return: |
-46.65% |
|
Average Annual Total Return: |
-6.09% |
|
Starting investment: |
$10,000.00 |
|
Ending investment: |
$5,334.80 |
|
Years: |
10.00 |
|
|
|
Date |
Ratio |
12/09/2020 | 1 for 10 |
|
|